A Partnership Model for the Control of Unethical Marketing of Medical Drugs in Nigeria. by Dike, Onwubiko N. & Onah, Julius O.
European Journal of Business and Management                                                                                                                               www.iiste.org 
ISSN 2222-1905 (Paper) ISSN 2222-2839 (Online) 
Vol.5, No.29, 2013 
 
1 
A Partnership Model for the Control of Unethical Marketing of 
Medical Drugs in Nigeria. 
Onwubiko N.  Dike1*,      Julius O.Onah2 
1. Department of Management Sciences, Rhema University, PMB.7021, Aba, Abia State, Nigeria.                                    
2. Department of Marketing, University of Nigeria, Nsukka, Enugu State, Nigeria.                                                                  
*E-mail of the corresponding author:atomslimited@yahoo.com 
Abstract                                                                                                                                                                 
The study assessed the effects of enforcement of anti-counterfeit drug laws (penalties) on the unethical 
marketing of medical drugs in Nigeria, particularly the South Eastern States. The study was a survey design. 
Stratified, simple random, convenience and judgmental sampling procedures were adopted. A research question 
and one null hypothesis guided the study. The population consisted of 5621 respondents, comprising 3444 
healthcare professionals, (doctors, pharmacists, nurses), 1641 drug consumers, 390 licensed drug firms and 146 
senior staff of the Regulatory Agencies in Abia, Anambra, Ebonyi, Enugu and Imo States. Five University 
Teaching Hospitals were used for the study. A sample of 985 respondents was used. Primary and Secondary 
sources of data were accessed. The questionnaire was validated using the opinions of experts. Pilot study was 
conducted and the scores subjected to Cronbach’s Alpha technique. The reliability coefficient was 0.947, 
indicating high degree of internal consistency of the research instrument .The mean (x) and criterion mean scores 
were used to answer the research question. Z-test statistical technique was applied in testing the hypothesis at 
0.05 level of significance and 4 degrees of freedom. The findings of the study revealed that enforcement of 
existing penalties had non-significant positive reduction in unethical marketing of medical drugs. The 
partnership model (Regulatory Excellence Model) was designed to enhance the control of unethical marketing of 
medical drugs in Nigeria and further recommendations were made.   
Keywords: Medical Drugs, Unethical Marketing, Model, Enforcement, Penalties, SDSI, NAFDAC.     
1.   Background of the Study. 
 With a population of over 150 million people, Nigeria represents a large market for medical drugs.  Medical 
drugs are the integral part of healthcare delivery system, faced with risks and uncertainties. They are expected to 
perform the multiple functions of restoring abnormal physical states, correcting or modifying organic 
malfunctions and preventing disease disorders in the human body or in animals (Okoye, 2005: 44). When the 
potency of the drugs cannot accommodate the functions of mitigation or prevention of disease disorder, 
uncertainties usually surround their production and they pose great risks to public health. Medical drugs are 
rarely sold directly from manufacturers to retailers or consumers. The dynamic link between manufacturers and 
consumers is bridged by a network of intermediaries, scattered across different countries in the globe. The 
complexity of the distribution chain makes it vulnerable for substitution of counterfeit drugs in the chain. The 
distribution chain consists of open markets, patent medicine stores, and community pharmacies, private and 
public hospitals. The patent medicine stores are owned by the holders of the patent and proprietary medicine 
vendors’ licenses. The major threat to the drug distribution chain is the secondary market, comprising small and 
loosely regulated wholesalers and retailers typically State licensed or registered companies scattered all over 
Nigeria. This market controls good chunk of the drug distribution network, using  their go-to-market approaches, 
namely, sale of counterfeit drugs, drugs that have degenerated due to poor storage and handling, drugs with 
wrong packaging / unapproved labels, drugs with fake NAFDAC numbers, drugs in unregistered pack sizes, 
including drugs re-labeling, re-validating of expired drugs, among others..Bulk packaged drugs are repackaged 
in smaller bottles for better commercial utility. Repackaging constitutes the greater vulnerabilities of the entire 
drug distribution chain with constant inflow of counterfeit drugs. Internet provides counterfeiters with new and 
powerful means to sell drugs through auction sites, stand-alone e-commerce sites and e-mail solicitations. The 
on-line environment is attractive to drug counterfeiters due to the relative ease of deceiving consumers (OECD, 
2007:14).The high profitability of drugs counterfeiting which exceeds that of illegal drug trades, with low risk of 
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detection and relatively light penalties, provide attractive environment for the inhuman business. Interpol has 
discovered a disturbing relationship between drug counterfeiting and terrorist activities. Drugs counterfeiting 
crime is becoming the preferred method of financing for a number of terrorist groups (OECD, 2007:15). 
Counterfeiters tend to have upper hand in view of the enormous volume of drugs being legitimately marketed 
and the ease with which counterfeit drugs can be concealed. They target drugs with high profit margins, taking 
into account, the size of the market to be exploited, the technological and distribution challenges associated with 
the undertaking (OECD,2007:11)Broad range of counterfeit drugs are produced and marketed as genuine drugs 
carrying holograms and other imprints (Okoghenun,2010:5).Recently,NAFDAC intercepted a drug whose 
original brand did not have hologram but the counterfeit had hologram and consumers were buying the 
counterfeit in place of the genuine drug (Oloja,et al,2011:16). The list of drugs subject to counterfeiting include; 
medicines for treatment of cancer, HIV, malaria, osteoporosis, diabetes, hypertension, cholesterol, 
cardiovascular disease, obesity, infections and prostate diseases, etc (OECD, 2007:12). The drugs are usually 
imported at the lowest costs possible and sold cheaper than genuine drugs.  These counterfeit drugs wind up in 
the bloodstreams of the unsuspecting patients. Thousands of drug consumers have been poisoned. When demand 
for an expensive drug is high, drug counterfeiters swap labels of two drugs manufactured by the same company, 
exploit similarity in appearance between the original preparations and the counterfeits, label low price drugs with 
high price labels and pass off a company’s drug product for another (Erhun, 2001:23). Other unethical practices 
of the drug firms include re-validating of expired drugs to bear future dates, wild drug performance /off—label 
claims, dishonest/misleading advertising, etc. The profound effects of counterfeit drugs on public health and the 
nation’s economy are rather unquantifiable. The Federal Government of Nigeria established the regulatory 
agencies to dictate how drug firms produce, promote, price and distribute their products. They include  National 
Agency for Food and Drugs Administration and Control (NAFDAC) which regulates foods, drugs and 
cosmetics, Pharmacists Council of Nigeria details the standards required for professional practices in line with 
international codes and Consumer Protection Council (CPC) provides speedy redress to consumer complaints 
and seeks ways and means of removing or eliminating from the market, hazardous products and causing 
offenders to replace such products with safer and more appropriate alternatives. In spite of the stringent measures 
adopted by the regulatory agencies, the nation is still experiencing high incidence of counterfeit drugs. Erhun (et 
al, 2001:32) attributed the preponderance of counterfeit drugs to the inadequacy of the laws governing 
pharmaceutical activities and the deficiency in the implementation and enforcement of the existing laws. 
Akunyili (2010:56) identified enforcement as the weakest link in the chain of regulatory activities. According to 
Chukwuemeka (et al, 2011:132), the drug regulatory policies in Nigeria are more than efficient. The weak 
regulatory regime as evidenced by the preponderance of counterfeit drugs in Nigeria was therefore attributed to 
poor enforcement of the existing drug laws, among others. This study focused on the effectiveness of the 
enforcement of the existing anti-counterfeit drug laws (penalties) on the unethical marketing of medical drugs in 
Nigeria, particularly the South Eastern States of Nigeria. 
1.1    Statement of the Research Problem. 
Most of the nation’s health policies like the National Programme on Immunization (NPI) and Roll Back Malaria 
Programme have suffered setbacks due to the challenges of counterfeit drugs. Studies have revealed strong 
positive correlation between counterfeit drugs and high failure rate in malaria treatment and control 
(Chukwuemeka, et al, 2011:132). Counterfeit drugs have been closely related to global public health problems, 
causing liver damage, kidney and heart failures, disabilities, injuries and even death (Akunyili, 2010:36).It has 
been estimated that upward of 2000 children per day die in Africa as a result of taking counterfeit malaria 
medications (Rago, 2009). The evil of counterfeit medicines is worse than the combined scourge of malaria, 
HIV/AIDS, armed robbery and illicit drugs and violates the right to life of consumers (Akunyili, 2010:36). 
Unethical marketing of medical drugs have debilitating effects on the nation’s economy. It reduces incentives to 
invest in the development of new medicines. Employment is affected as jobs are lost due to drugs counterfeiting. 
Counterfeit drugs crowd genuine drugs out of the market and exert downward pressures on prices. Brand images 
and reputations of genuine drug firms are damaged. Governments loose much revenue as drug counterfeiters 
evade taxes. Potential losses include corporate income taxes, value added taxes, excise taxes, import tariffs and 
social insurance charges. Criminal networks and organized crimes thrive through drug counterfeiting. Terrorists’ 
activities are financed and public institutions are weakened when criminals bribe officials to market counterfeit 
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drugs at the expense of public health. Huge amount of resources are wasted in combating drug counterfeiting. 
Counterfeit drugs impact negatively on the country’s gross national product (GNP) as productivity is greatly 
hampered (Okoye, 2005:49). Destruction of seized drugs also raises environmental issues. Foreign direct 
investments are affected by drug counterfeiting. When an action or choice is motivated by the desire to do a right 
thing, it is ethical (Bovee, et al, 1992:62). If the action is motivated by the desire to do a wrong thing or avoid 
doing the right thing, it is unethical. The pharmaceutical activities of manufacturing and marketing of counterfeit 
drugs are clearly unethical. The Regulatory Agencies have adopted stringent measures to regulate the activities 
of the drug firms within the framework of the existing drug laws. Various penalties were imposed to ensure 
ethical compliance. In spite of the elaborate safety measures, strict regulations and battalion of enforcement 
personnel of the regulatory agencies, the stream of counterfeit drugs continues unabated. The contributory 
factors as outlined by (Erhun, et al, and 2001:27) include ineffective enforcement of the existing laws, high cost 
of genuine drugs, loose control systems and corruption, among others. In view of these contending factors, the 
study was designed to determine the effects of enforcement of existing penalties on the unethical marketing of 
medical drugs in Nigeria with the aim of proffering solutions. 
1.2 Objectives of the Study. 
The broad objective of the study is to design a partnership model for effective control of the unethical marketing 
of medical drugs in Nigeria. The specific objective is to assess the effects of the enforcement of the existing anti-
counterfeit drug laws (penalties) in the control of the unethical marketing of medical drugs in Nigeria, 
particularly the South Eastern States. 
1.3 Research Question. 
To what extent has the enforcement of existing penalties contributed to the reduction of unethical marketing of 
medical drugs in Nigeria, particularly the South Eastern States? 
1.4 Delimitation of the Study.  
 The five University Teaching Hospitals in the South Eastern States of Nigeria constituted the study centers and 
included;Abia State University Teaching Hospital, (ABSUTH), Abia State; Ebonyi State University Teaching 
Hospital,(EBSUTH),Ebonyi State; Imo State University Teaching Hospital, (IMSUTH), Imo State; Nnamdi 
Azikiwe University Teaching Hospital, (NAUTH), Anambra State;  University of Nigeria Teaching Hospital, 
(UNTH), Enugu State. The study was extended to the South-East Offices of the National Agency for Food and 
Drugs Administration and Control (NAFDAC), Pharmacists Council of Nigeria (PCN) and Consumer Protection 
Council (CPC). The Standard Organizations of Nigeria(SON) was not relevant to this study because it regulates 
and controls all items except the seven categories of item regulated by NAFDAC,  medical drugs inclusive 
(Akunyili, 2010:99). The study covered a decade of activities in the Nigerian drugs market, ranging from 2001 to 
2011. 
1.5 Hypotheses of the Study. 
To guide the study, these hypotheses were formulated and tested at 0.05 level of significance;                                                   
Ho: The enforcement of existing penalties has no significant effects on the unethical marketing of medical drugs.             
H1: The enforcement of existing penalties has significant effects on the unethical marketing of medical drugs.  
     2.  Review of Related Literature. 
2.1 Theoretical Framework. 
The study was anchored on the Social Control theory, postulated by E.A. Ross in 1901 and further developed as 
Social Bonding theory by Travis Hirschi (Hirschi, 1969:18-20). The theory is concerned with how human 
behavior is regulated within the society. It stipulates that people are inherently motivated to deviance and due to 
social bonds and fear of punishment; they do not act on these instincts.. It specifies that no society can afford to 
denounce criminal activity, without duly accepting its responsibility because most delinquent behavior is the 
result of “unmonitored” social control by the authorities (Borade, 2010). The Social Control theory insists that it 
is mostly people that have nothing to lose by conforming to delinquency who are drawn toward the anti-social 
behavior of exchanging human lives for financial gains. Increasing the penalties for non-conformity may curb 
the inhuman activities of these nothing –to- lose people. The import of the Social Control theory is the crucial 
role of the society, viz, the Government (Executive, Legislature & Judiciary), regulators, operators, drug 
consumers, public, traditional rulers & religious leaders, in the control of the unethical marketing of medical 
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drugs. According to Wolpe (1988), every individual in the society must see himself as a moral entrepreneur, 
saddled with the responsibility to challenge definitions of deviance.  
2.2ConceptualFramework.                                                                                                                              
Drug regulation is the totally of all measures which governments take to ensure the safety, efficacy and quality 
of drugs, as well as the relevance and accuracy of product information (Ratanawijitrasin, et al, 2002: 7-8). The 
success or failure of drug regulation however depends on implementation. The regulation of medical drugs has 
four dimensions, viz, administrative elements, regulatory functions, technical elements and level of regulation 
(Ratanawijitrasin, et al, 2002:12). The administrative components are the input factors that allow for functioning 
of drug regulation, including policy, legislation /regulation, organizational structures, human and financial 
resources and mechanism for planning, monitoring and evaluation. The regulatory functions include licensing of 
persons, premises, inspections of pharmaceutical establishment (market authorization), quality control, control of 
drug promotion/advertisement, monitoring of adverse drug reaction (ADR) and speedy redress of consumer 
complaints through negotiations, mediation and conciliation. The technical elements include the existence and 
type of standards, norms, guidelines, specifications and procedures. The level of regulation indicates level at 
which the various regulatory functions are performed. It should be noted that the political structure of any 
country determines the overall governance of drug regulation. 
 
Environment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        Environment 
 
Figure 2.1. Drug regulation: Interconnections between structures, processes and outcomes. 
    Source: Ratanawijitrasin, S and Wondemagegnehu, E., (2002: 120). Effective Drug Regulation, A 
Multicountry Study. Malta: World Health Organization, Library Cataloguing-In-Publication Date. NLM 
Classification. QV 33:120.                                                  
Figure 2.1 shows the interconnections between regulatory structures, process and outcomes. The framework 
enhances an understanding of the fundamentals of drug regulation and control. In assessing drug regulatory 
performance, it is imperative to consider the following steps; identify regulatory structures, decide whether the 
regulatory processes are well designed and implemented, measure intermediate outputs at the individual 
regulatory function level and measure the final outcomes to ascertain whether drug regulation objectives have 
been met( Ratanawijitrasin,  et al, 2002: 118). The regulatory structures are the legal and administrative settings 
of the agencies, charged with the responsibility of drug regulation. The legal support involves granting legal 
authority to the agencies to perform regulatory functions and impose sanctions when violations occur. The drug 
regulatory processes entail the application of appropriate methods and strategies to implement the activities. The 
outcomes are the final results obtained when the regulatory agencies carry out the different regulatory activities 
and functions. Outcomes can be measured in terms of quality of pharmaceutical products marketed, proportion 
of licensed pharmaceutical facilities, proportion of pharmaceutical facilities meeting certain required 
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standards,eg,GMP, number of illegal products and number of illegal facilities (Ratanawijitrasin, et al, 
2002:9).Outcomes are often not readily measurable because a long period of time may elapse before relevant 
outcomes can be seen. If the regulatory performance is effective, safe, effective and good quality drugs will be 
available in the market with accurate information on the labels and inserts and the functions of prescribing and 
dispensing drugs by healthcare professionals become achievable. The public will be assured of better treatment 
in the event of illness and prevention against diseases with attendant reduction in morbidity and mortality rates. 
With ineffective drug regulation, the outcomes are devastating, viz, substandard, counterfeit, toxic and useless 
drugs find their ways into the bloodstreams of patients, causing serious injuries and even death. Unethical 
marketing practices like label tampering, deceptive advertising, mixing of counterfeit with genuine drugs, 
irrational prescription and dispensing are features of lax regulation, with eventual health outcomes like drug 
resistance, treatment failure, adverse drug reactions and persistent illness, leading to increased morbidity & 
mortality. The effectiveness of the measures adopted by the regulatory agencies relates to the drug efficacy, 
safety, quality and rational use objectives (Ratanawijitrasin, et al, 2002:121). The efficacy objective is achieved 
when the drugs available in the market are efficacious for stated diseases and conditions. No counterfeit drugs 
are distributed. When the drugs are adequately safe and possess correct active ingredients, the safety and quality 
objectives are attained. If the drugs are used in accordance with approved claims and methods, the rational use 
objective is achieved. 
 
2.3    Business Excellence Model 
 
Figure 2.2 The Business Excellence Model. 
Source: Oakland, J., S., (1999) “Total Quality Management (TQM) “in the IEBM Encyclopedia of Marketing, N. 
J. Baker; London: Thomson Learning.  
Quality service delivery by the regulatory agencies can be achieved through the application of Business 
Excellence Model (Oakland, 1999:698). Business Excellence Model (BEM) as an aspect of Total Quality 
Management, (TQM) has been used to change individual minds and attitudes as well as communities and 
nations. TQM directly and covertly alters the values, culture and mind-sets within an organization. BEM 
incorporates nine functional areas, viz, leadership, people management, policy and strategy, resources, processes, 
people satisfaction, customer satisfaction, impact on society and business results (Oakland, 1999:698).  As 
shown in figure 2.2, effective leadership drives policies and strategies, using available resources and working 
through people in the organization to achieve desired goals. The transformation processes which include actions, 
methods and operations lead to the satisfaction of customer needs and expectations, culminating into people 
satisfaction. The impact on the society reflects public good, with the attendant financial and non-financial 
implication. The application of the Business Excellence Model demands senior management’s total commitment 
to manage processes, change the culture of the organization, improve communication and focus on the customer 
welfare. The model aims at changing mind-set from the old ways of doing things to the new, from the past to the 
future. People’s management involves transformation of the individuals both in the regulatory agencies and the 
drug firms.The transformed individual will perceive new meaning to his life, to events, to duties, to members of 
the public and to interactions between his colleagues. The individual will have a basis for judgment of his own 
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decision and for transformation of the organization he belongs to. He will understand the system he works in and 
apply its principles in every relationship with other people. BEM insists that top management develops problem 
prevention mentality. A complete change of mindset is required to unscramble the intuition of rushing into 
inspection/ detection mode in tackling the problems of unethical marketing of medical drugs. The deficiency of 
the strategy of detection has been the bane of drug regulation in Nigeria. The strategy of prevention is 
appropriate, even if it entails stiffer penalties to establish the culture of deterrence. The top management has a 
responsibility to develop a mission statement that will be strictly adhered to, identify the critical success factors 
and outline processes for continuous improvement of regulatory standards. By implication, the core of Total 
Quality Management is the involvement of everybody. The unethical marketing of medical drugs must be 
challenged by every citizen of this country and should not be the exclusive duty of the regulatory agencies. The 
Regulatory Excellence Model (REM) was derived from the partnership concept. 
 
2.4   Constraints to Implementation of Business Excellence Model. 
The constraints faced by chief executives and directors in the implementation of the Business Excellence Model 
are mainly in the area of proliferation of theories and packages. The operators get confused and irritated as the 
tasks of implementation become daunting. Failure to meet the requirement in any part of the quality chain has a 
multiplier effect. Failure in one part of the system creates problems elsewhere, leading to yet more failures and 
more problems. (Oakland, 1999: 687).  
 
3. Methodology 
The survey research design was used. The target population was 5621, comprising Healthcare Professionals 
(3444); Licensed Drug Firms (390); Drug Consumers (1641) and Regulatory Agencies (146). The stratified, 
simple random, convenience, judgmental sampling procedures were adopted as the sampling techniques. The 
sample size was determined using Yamane (1967 cited in Eboh, 2009:94) formula, i.e,n =N /I + N(e)2   ,where, n 
=sample size,N=actual population, e =level of significance, I =constant. The sample size for each category of 
respondents was estimated using Bowley’s proportional allocation statistical technique; nh = nNh /N, where, nh 
= the number of unit allocated to each category of respondents. Nh = the number of respondents in category, n 
=the total sample size N= total population. The sample size for this study was 985, made up of HCP (358); Drug 
Consumers (322), Licensed Drug firms (198) and Regulatory Agencies (107).Data were generated from both 
primary and secondary sources. The sources of primary data included questionnaires, focused group discussions, 
personal (face to face) interviews and observations. The questionnaire embraced the use of five point Likert 
Scale format, viz, Strongly Agree (5points), Agree (4points), Undecided (3points), Disagree (2points) and 
Strongly Disagree (1point) with the aggregate(criterion)mean score of 3.0. The instrument was subjected to face- 
to – face validity by giving it to marketing experts who examined the items to ensure they were in line with the 
objectives of the study. The instrument was checked for reliability using Cronbach’s Alpha technique. Pilot 
survey was used. A total of sixty respondents were administered with sixty copies of questionnaires. Each 
category of respondents was served with fifteen copies of questionnaires. The return rate was hundred percent. 
Five copies of the questionnaires were rejected due to inconsistencies and fifty five analyzed. The reliability 
coefficient was 0.947, indicating high degree of internal consistency of the research instrument. A total number 
of 985 questionnaires were distributed, 898 were returned, representing 91.2 percent while 87 were not returned, 
(8.8 percent). Out of the 898 returned questionnaires, 32 were rejected, representing (3.60 percent) due to 
discrepancies while 866, representing 96.40 percent were utilized for the study. The hypothesis of the study was 
tested, using Z-test (two-tail) statistics, at 0.05 level of significance and four degrees of freedom. 
4.    Data Presentation and Analyses  
      The data derived from the study were presented in tables and analyzed as shown below.  
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Table 4.1.        Literacy Levels of Respondents. 
Qualifications Regulatory 
Agencies  
Licensed 
Drug 
Firms 
Drug 
Consumers  
Healthcare 
Professionals 
Total  Percentage 
WASC/SSC/ 
GCE 
_ 124 57 10 191 22.0 
OND/NCE/RN - 11 34 69 114 13.2 
HND/BSC/BA 76 35 127 102 340 39.3 
MBBS - - - 108 108 12.5 
MSc, MBA, 
MPhil, PhD 
20 5 65 23 113 13.0 
Total 96 175 283 312 866 100.0 
              Sources: Field Survey, 2011. 
Table 4.1 showed that 39.3 percent of the respondents had first degree/Higher National Diploma certificates, 13 
percent were holders of Ordinary National Diploma, National Certificate in Education/Registered Nursing 
Certificates and Masters/Doctor of Philosophy degrees respectively. The medical doctors were 12.5 percent 
while 22 percent of the respondents had ordinary level school certificates. Majority of the holders of the West 
African School Certificates/ General Certificates of Education (124, representing 14.0 percent of the 
respondents) were proprietors of the licensed drug firms, indicating the dominance of non-professionals in drug 
business. 
 
              Table 4.2.      Usage Rate of Medical Drugs. 
  
                     Source: Field Survey, 2011. 
Table 4.2 showed that the four categories of respondents were consumers of medical drugs. The weekly 
consumption rate was 38.7 percent, followed by daily (30.0 percent), and monthly (26.9 percent). Only 4.4 
percent of the total number of respondents rarely used drugs. The findings implied that any respondent could be 
a victim of counterfeit medications. 
4.1. Research Question:  
To what extent has the enforcement of existing penalties contributed to the reduction of unethical 
marketing of medical drugs in South East, Nigeria? 
Rate  Regulatory 
Agencies  
Licensed 
Drug Firms 
Drug 
Consumers 
Healthcare 
Professionals 
Total Percentage  
Daily  21 45 136 58 260 30.0 
Weekly  50 74 117 94 335 38.7 
Monthly 25 46 30 132 233 26.9 
Rarely - 10 - 28 38 4.4 
Total  96 175 283 312 866 100.0 
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Table 4.3.     Use of Mean (X) Scores of Respondents to Answer the Research Question. 
Item  Statement Agree. 
SA+A 
Disagree 
U+D+SD 
Total 
scores 
Total no of 
respondents 
Mean 
score 
Result 
1 The enforcementof existing penalties has reduced the cloning of fast 
moving drugs in South East, Nigeria. 
2339  295 2634 866 3.04 Accepted 
2 The enforcement of existing penalties has reduced the marketing of 
drugs with zero active ingredients and fake NAFDAC numbers. 
2105 402 2507 866 2.89 Not 
accepted 
3 The terrorist activities funded through 
drugscounterfeiting hasreduced asa result of enforcement ofexisting. 
penalties 
1856 524 2380 866 2.75 Not 
accepted 
4 Enforcement of existing  penalties  has  curbed the marketing 
of degenerated drugs  arising  from  broken cold chains and poor 
handling 
1413 546 1959 866 2.26 Not 
accepted  
5 The marketing of drugs in unregistered pack 
sizes/unapproved labels and withoutexpiry dates has reduced due 
to enforcement of existing penalties. 
2065 394 2459 866 2.84 Not 
accepted  
6 The enforcement of existing penalties has reduced the marketing of 
expired and revalidated drugs. 
1825 594 2419 866 1.80 Not 
accepted 
7 The enforcement of existing penalties has led to permanent closure 
of the facilities of the illegitimate drug wholesalers and retailers in 
South East, Nigeria. 
986 1007 1993 866 2.30 Not 
accepted  
8 The marketing of drugs with active ingredients different 
and unrelated to the inscriptions on their labels has reduced due to 
enforcement of existing penalties. 
1191 923 2114 866 2.44 Not 
accepted  
 Total 13780 4685 1845 6928 21.2  
 Aggregate mean  1723 586 2308 866 2.67 Not 
Accepted 
Source: Field Survey, 2011.                                            
The mean, 3.0, was used as a criterion for accepting or not accepting the statements of the questionnaire in order 
to answer the research question (Nwankwo, 2011: 244).  The rule is that any statement with mean score of 3.0 
and above is accepted as a true statement and any with mean score below 3.0 is unacceptable. Table 4.3 showed 
that item 1 had mean score of 3.04, indicating that the enforcement of existing penalties has reduced the cloning 
of fast moving drugs in South East Nigeria. Items 2 to 8 had mean scores below 3.0. The enforcement of existing 
penalties therefore had not contributed to reduction in the marketing of drugs with zero active ingredients and 
fake NAFDAC numbers, drugs that have degenerated due to improper storage, drugs in unregistered pack sizes/ 
unapproved labels and without expiry dates, and drugs with active ingredients different and unrelated to 
inscriptions on their labels. The terrorist activities funded through drug counterfeiting and marketing of expired 
/revalidated drugs has not reduced as a result of enforcement of existing penalties. The facilities used by the 
counterfeiters in the inhuman business had not been completely shut down through the enforcement of the 
existing penalties. The aggregate mean of 2.67 for the research question, indicated that the enforcement of the 
existing anti-counterfeit laws (penalties) had not contributed to remarkable positive reduction in the unethical 
marketing of medical drugs in South East, Nigeria.                                                                                           
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Table 4.4           Analysis of Responses 
Item No of Resp.              
Agree (A) 
Scores of 
Resp.A 
Mean of 
Scores 
(Xa)  
Std. Dev. 
of Scores. 
A (SDa) 
No. of Resp. 
Disagree (D) 
Scores of 
Resp. D 
Mean of 
Scores 
(Xd) 
Std Dev. 
on scores 
SDd 
Total No. 
of Resp. 
1 694 2339 3.37 23.40 172 295 1.72 22.25 866 
2 624 2105 3.37 15.30 242 402 1.66 11.85 866 
3 557 1856 3.33 5.64 309 524 1.70 3.53 866 
4 434 1413 3.26 1490 432 546 1.26 1.93 866 
5 624 2065 3.31 13.70 242 394 1.63 12.37 866 
6 550 1825 3.32 4.35 316 594 1.88 0.55 866 
7 322 986 306 41.14 544 1007 1.85 18.07 866 
8 367 1191 3.25 27.81 499 923 1.85 15.10 866 
Total 4172 13780 26.27 146.24 2756 4685 13.55 85.65 6928 
Aggregate 
mean  
521 1723 3.28 18.28 345 586 1.69 10.71 866 
Source: Field Survey, 2011. 
Table 4.4 showed the means and standard deviations of the responses on the effects of enforcement of existing 
drug laws (penalties) on the unethical marketing of medical drugs. The calculated Z-value shown in Table 4.5 
was derived from Table 4.4. 
Table 4.5        Test of hypothesis  
Responses  No          
          of 
responde
nts, N 
Mean  
    X 
   Std 
Deviation   
SD 
Degrees 
of 
freedom 
DF 
Z- 
calculated 
Z- 
critical 
Level of 
signific
ance 
Decision 
Agree 521 3.28 18.28  
    4 
 
+1.15 
 
 
 _+1.96 
 
  
Disagree 345 1.69 10.17  0.05 
 
Accepted  
Source: Field Survey, 2011                                            
Table 4.5 showed that the calculated Z-value (+1.15) was found in the region between -1.96 and +1.96 (i.e. 
critical values of Z) at 4 degrees of freedom and 0.05 level of significance. In applying the decision rule, the null 
hypothesis was not rejected. The p-value provided additional insight into the decision. The probability of finding 
a Z-value as extreme as +1.15 was 0.5000-0.3749 = 0.1251.The two-tailed p-value, 2(0.1251) = 0.2502, was 
greater than the significance level of 0.05 (i.e. P > 0.05). The null hypothesis was therefore not rejected and the 
conclusion that the enforcement of existing penalties had not contributed to significant positive reduction in 
unethical marketing of medical drugs was upheld to be true.                              
5.   Discussion of Findings. 
 The literacy level of the drug distribution chain members was low. Out of 175 operators of the drug firms 
involved in the study, 124(representing 71.0 percent), possessed the ordinary level school certificates and only 
35 (20 percent) had first degree/ Higher National Diploma Certificates. These firms were officially licensed to 
distribute and market medical drugs in the South Eastern States of Nigeria by the Pharmacists Council of Nigeria 
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(PCN). Some chain members were granted the Patent and Proprietary Medicine Vendors’ license to sell only 
over-the –counter (OTC) drugs. In practice, they sold all categories of drugs, including Prescription-Only-
Medicines and the minimum qualification to obtain the license is First School Leaving Certificate. The non-
professionals with virtually little or no education dominated the drug business as importers, wholesalers and 
retailers in the open drug markets. According to Erhun, (et al, 2001:24), the involvement of these unqualified 
persons in the procurement and distribution of medical drugs had its implications in drug regulation and control 
in Nigeria. Usually, these unqualified persons do not have much at stake in terms of conformity to professional 
standards and their business interests are motivated by the desire to get-rich-quick. The Social Control theory 
stipulates that it is mostly these people that have nothing to lose by conforming to delinquency who are drawn 
toward the anti-social behavior of exchanging human lives for financial gains. These distribution chain members 
have been associated with the unethical marketing of medical drugs through direct involvement in drug re-
packaging, compounding of syrups/lotions, revalidating of expiry date and distribution of counterfeit drugs. 
Erhun (et al, 2001:23-34) corroborated this finding by relating the activities of non-professionals in drug 
business to the preponderance of counterfeit drugs in Nigeria. Since legal provisions are essential for attaining 
regulatory goals, the implementation must be backed by law. All laws are meaningless unless they are enforced 
(Peter, 1989). The Nigerian drug regulatory environment is characterized by weak enforcement regime. Weak 
enforcement regime implies that either the counterfeiters are not sufficiently penalized for their actions or that 
the enforcement process is lax or both. The findings of the study revealed that the enforcement of the existing 
penalties (anti-counterfeit laws) by the regulatory agencies had not contributed significantly to the reduction in 
unethical marketing of medical drugs in South East, Nigeria. According to Erhun (et al, 2001:23-34), the 
enforcement of the various drug laws in Nigeria had been deficient. It was also revealed that the laws governing 
the manufacture, sales, distribution, importation and exportation of drugs were not adequate enough to control 
the inhuman trade. Akunyili (2010:56) affirmed that poor enforcement was contributory to the weak enforcement 
regime in this country. The devotion of insufficient resources to enforcement and inappropriate penalties for 
offences were adduced as being responsible for the weak enforcement regime. Considering the outcomes at each 
regulatory functional level, the study revealed that the enforcement of existing penalties had not reduced the 
marketing of drugs with zero active ingredients and fake NAFDAC numbers, drugs in unregistered pack 
sizes/unapproved labels and without expiry dates. The marketing of drugs that have degenerated due to broken 
cold chains/poor storage and unrelated to the inscriptions on their labels, abound in Onitsha Bridge Head and 
Aba drug markets. Terrorists had found drug counterfeiting a preferred method of financing their activities due 
to low risk of detection and relatively light penalties, compared to illegal drug trades. The enforcement of 
existing penalties had not imposed restrictions on the criminal networks and organized crimes. The cloning of 
fast moving drugs however had minimized in the South Eastern States of Nigeria due to the enforcement of 
existing anti-counterfeit drug laws. Available records have shown instances where the counterfeiters were 
neither punished under the law nor the enforcement actions publicized to act as deterrent. When the Pharmacist 
and Director of Tomak Pharmacy in Port Harcourt was arrested in 2008, for distributing counterfeit baby 
teething mixture, my pikin, and other unregistered drugs. No record of enforcement actions against the 
pharmacist was made public (Akunyili, 2010: 124). According to Akunyili (2005:28), the efficiency of the 
regulatory staff has been adversely affected by corruption and conflicts of interests, resulting in laws not being 
enforced and criminals not being arrested, prosecuted and convicted for crime.  The operations of NAFDAC in 
South East and Onitsha in particular suffered a setback due to the refusal of the Abuja High Court Judge to allow 
trials of several people implicated in the assassination attempt of the former Director- General of NAFDAC, 
Professor Dora Akunyili.This unfortunate ruling actually emboldened the drug distribution chain members not 
only to resist inspections but also attack the regulatory staff. On June 3, 2006 the staff of NAFDAC and twelve 
armed policemen were physically attacked and driven out of Onitsha Head Bridge drug market by the 
counterfeiters. Six operational vehicles belonging to NAFDAC were destroyed (Akunyili, 2010:128). NAFDAC 
neither took enforcement actions nor subsequently commenced mass arrests of the counterfeiters for purposes of 
prosecution in the court till date. On October 26, 2010 the Pharmacists Council of Nigeria raided the Tenant 
Road drug market, Aba and recovered large volumes of counterfeit drugs. An anti-inflammatory analgesic, 
Phenylbutazone, with life threatening adverse reactions on bone marrow depression and renal failure was 
recovered. No record of enforcement of penalties was available. The drug market was re-opened on December 
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21, 2010 based on court order, boosting the confidence of the counterfeiters (Field Survey, 2011). The Social 
Control theory stipulates that people are inherently motivated to deviance and due to social bonds and fear of 
punishment, they do not act on these instincts. The theory further states that it is the responsibility of the control 
mechanisms like the law, enforcement agents and the physical paradigms within the community, to effectively 
and periodically address delinquent behaviors. The anti-social behaviors of the counterfeiters were indications of 
lack of major stakes (social bonds) in the community. Increasing the penalties for non-conformity and strictly 
enforcing them would help to address the delinquent behaviors of these nothing-to-lose people in our society. 
Since the enforcement of anti- counterfeit drug laws could not provide strong deterrence against unethical 
marketing of medical drugs, serious gap exists in curbing this inhuman business in Nigeria. Counterfeiters do not 
give up easily and have to be dislodged, roots and branches through a vote of no confidence from every drug 
consumer. According to Wolpe (1988), every individual consumer in the society must see himself as a moral 
entrepreneur, saddled with the responsibility to challenge the unethical marketing of medical drugs. This grave 
situation provoked the emergence of a cross-sector partnership forum in this study, referred to as Regulatory 
Excellence Model (REM).  
5.1. The Regulatory Excellence Model (REM)   
 
Figure 5:1 The Regulatory Excellence Model. Source: Adapted from Oakland, J. S. (1999: 697) “Total Quality 
Management (TQM)” In The IEBM Encyclopedia of Marketing, M.J. Baker, London Thomson Learning, for the 
purpose of this study. 
 
The Regulatory Excellence Model was adapted from the Business Excellence Model and anchored on the 
framework of Ratanawijitrasin (et al, 2002:120) and the principles of Total Quality Management. It is an attempt 
at developing a cross-sector partnership forum for effective control of the unethical marketing of medical drugs 
in Nigeria. The Model has nine components, viz, structures, resources, policies and strategies, people 
management, regulatory processes, impact on society, customer/ people satisfaction and regulatory outcomes 
(figure,5.1). The structures include the formation of Stakeholders’ Drug Safety Initiative (SDSI) by the collective 
efforts of the Chief Executives or top representatives of the Regulatory Agencies, Pharmaceutical industry and 
the Consumer Association. The SDSI should be carefully replicated in the thirty-six states of Nigeria, including 
Abuja and at the Local Government Councils levels. The aims and objectives of the Stakeholders’ Drug Safety 
Initiative must be clearly defined and expressed in a mission statement at the national Level and effectively 
communicated down the line. The leadership hierarchy must be composed of individuals of proven integrity and 
totally committed to the shared vision of promoting public health. The stakeholders and the governments should 
collectively fund the initiative through value added taxes, certain percent of the profits of the drug firms 
(pharmaceutical industry), Internally Generated Revenues (IGR) from the Regulatory Agencies and special 
allocations from both federal, state and Local governments/ trade associations’ contributions. The leadership of 
the Stakeholders’ Drug Safety Initiative shall develop effective policies and strategies and create the resources 
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for achieving the mission or vision of the forum. All controls and procedures, quality audit and management 
review guidelines must be properly stated. The top management of the Stakeholders’ Drug Safety Initiative must 
adopt strategic overview of quality service delivery. Developing a problem prevention mentality to unscramble 
the intuition of rushing into detection / inspection mode to solve regulatory problems is important. The 
regulatory processes involve working with and through people. The style of managing people must undergo 
transformation. The first step is the transformation of the individual staff. The individual when transformed will 
perceive new meaning to his life, to events and to interactions between people. He will have a basis for judgment 
of his own decisions and for the transformation of the organization he belongs to. The individual will understand 
the system he works in and apply its principles in every kind of relationship with other people. The experts in 
any business are the people who do the job every day of their lives. The energy that lies within them can be 
released into the organization through education, training, encouragement and involvement (Oakland, 1999:655). 
Attention must be paid to staff, making sure they are capable of meeting the regulatory challenges. Effective 
communication within the organizations, up, down and across stakeholders must be encouraged for strong co-
ordination of the battle against unethical marketing of medical drugs.  The commitment of every stakeholder 
from the top management to the junior cadre is indispensible because human lives are endangered. The 
Stakeholders’ Drug Safety Initiative must consign regulatory functions to stakeholders on the basis of their areas 
of specializations. The pharmaceutical industry, for example, should undertake the task of tracking every step of 
how drugs are manufactured, imported and distributed in the country. Securing the actual drug product, its 
packaging and the movement through the drug distribution chain using cutting edge technological devices should 
be the functions of the Pharmaceutical industry. The Regulatory Agencies, among others, should heighten 
surveillance and awareness creation through sensitization programmes. The Consumer Association should 
embark on the education of members using well established communication networks. The consumers should be 
aware of their rights to safety, to accurate drug information and their responsibility to report counterfeit drug 
incidents promptly to the association. Public enlightenment workshops should be organized by the Consumers 
Association to educate members on the use of technological devices to detect counterfeit drugs and increase their 
perceptions of the dangers inherent in their preference for cheaper drugs. The collective responsibility of the 
stakeholders in the regulatory activities would lead to transparency in the activities of the drug firms. The 
resultant effects of the Stakeholders’ Drug Safety Initiative in the society would be the promotion of public and 
economic health of the nation. The measures of the successes or failures of the Regulatory Excellence Model are 
the outcomes. The structural and process factors affect regulatory outcomes. Quality regulatory activities would 
ensure the availability of safe, efficacious and quality drugs, appropriate drug information, rational drug use and 
appropriate dispersing. The health outcomes include better treatment of illness, better prevention of disease and 
decreased morbidity and mortality. Non-commitment in the application of the Regulatory Excellence Model 
would invariably lead to weak regulatory regime. The consequences include the preponderance of counterfeit, 
toxic and useless drugs in the markets and health centers, inappropriate drug information and irrational use of 
drugs, among others. The health outcomes manifest in drug resistance, treatment failure, adverse drug reactions, 
increased morbidity and mortality.  
 
 
5.2. Conclusion      
The pharmaceutical activities of manufacturing, importing, exporting and marketing of counterfeit drugs are 
clearly unethical. The study revealed that the enforcement of the anti-counterfeit drug laws(penalties) had non-
significant positive reduction in the unethical marketing of medical drugs in the South Eastern States of Nigeria. 
It is imperative therefore to note that the regulatory agencies acting as lone rangers in the Nigerian regulatory 
environment may be incapable of controlling the unethical marketing of medical drugs effectively. All the 
stakeholders, viz, the regulatory agencies, pharmaceutical industry (drug firms), healthcare professionals/ 
consumers (public) must brace up to challenge this inhuman business. Regulatory Excellence Model involves the 
enlistment of every sector of the society, viz, the government (Executive, Legislative, Judiciary), the public, the 
traditional institutions, religious leaders, trade/women/youth associations, media, students, etc, in the fight 
against the unethical marketing of medical drugs. The concerted efforts of the people would publicize and 
reinforce the enforcement actions to make the trade a taboo. The total commitment of the stakeholders to the 
shared vision, anchored on formidable leadership structures would drive effective regulatory processes to the 
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desired outcomes. Total consumer protection is a collective effort and its actualization demands collective inputs 
of the stakeholders. Counterfeit medicines are terrorizing the public and economic health of our nation. 
 
5.3.       Recommendations.                                                                                                                                                   
These recommendations were made in an attempt to control the unethical marketing of medical drugs in Nigeria, 
especially in the South Eastern States. The stakeholders have significant roles to play in this partnership venture. 
1. The stakeholders should establish powerful consumer association, comprising public/civil servants, 
professional and trade associations, labor unions, students, etc, to assert the rights of the consumers and enhance 
their responsibilities.  
2. The stakeholders, viz, the regulatory agencies, pharmaceutical industry and consumer association should 
jointly form cross-sector partnership forum (i.e. Stakeholders’ Drug Safety Initiative, SDSI), to develop common 
unified actions for the control of the unethical marketing of medical drugs. 
3. The leadership of the Stakeholders Drug Safety Initiative should be totally committed to the application of the 
Regulatory Excellence Model, to effect the reduction of the production, importation and marketing of counterfeit 
drugs to the barest minimum. 
   4. A high powered Stakeholders’ Continuous Quality Improvement Team should be established with  the 
oversight function of maintaining quality service standards and enforcement of anti-counterfeit drug  laws. 
 5. The Government should strengthen the legal frameworks which include life jail terms for defaulters and 
corrupt regulators, confiscation of their property, establishment of Consumer Courts (of High Court Status) in all 
the States, permanent closure of open drug markets, imposition of three months prison terms to ward off 
intervention of “Very-Important Persons” in regulatory activities and ensure the security of the regulators. 
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